Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study.

Cardiovascular Diabetology
Anne GillJames Malone

Abstract

Cardiovascular effects of glucose-lowering agents are of increasing interest. Our aim was to assess the effects of the glucagon-like peptide-1 receptor agonist exenatide on heart rate (HR) and blood pressure (BP) in subjects with type 2 diabetes mellitus (T2DM). In this double-blind, placebo-controlled trial, subjects with T2DM on metformin and/or a thiazolidinedione were randomized to receive exenatide (5 microg for 4 weeks followed by 10 microg) or placebo BID for 12 weeks. Heart rate and BP were assessed with 24-hour ambulatory BP monitoring. The primary measure was change from baseline in mean 24-hour HR. Fifty-four subjects (28 exenatide, 26 placebo) were randomized and comprised the intent-to-treat population. Baseline values (exenatide and placebo) were (mean +/- SE) 74.4 +/- 2.1 and 74.5 +/- 1.9 beats/minute for HR, 126.4 +/- 3.2 and 119.9 +/- 2.8 mm Hg for systolic BP (SBP), and 75.2 +/- 2.1 and 70.5 +/- 2.0 mm Hg for diastolic BP (DBP). At 12 weeks, no significant change from baseline in 24-hour HR was observed with exenatide or placebo (LS mean +/- SE, 2.1 +/- 1.4 versus -0.7 +/- 1.4 beats/minute, respectively; between treatments, p = 0.16). Exenatide therapy was associated with trends toward lower 24-hour, daytime, ...Continue Reading

References

Jun 5, 2003·Journal of Hypertension·Ming YuRichard J Roman
Sep 9, 2004·American Journal of Physiology. Endocrinology and Metabolism·Thomas NyströmAke Sjöholm
Sep 10, 2004·The Journal of Pharmacology and Experimental Therapeutics·Lazaros A NikolaidisRichard P Shannon
Nov 25, 2005·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Inga ThrainsdottirLars Rydén
May 15, 2007·Gastroenterology·Laurie L Baggio, Daniel J Drucker
Feb 7, 2009·Journal of the American College of Cardiology·Leo TimmersImo E Hoefer
Apr 23, 2009·Diabetes, Obesity & Metabolism·R GentilellaC M Rotella
Oct 21, 2009·International Journal of Clinical Pharmacology and Therapeutics·H LinnebjergM Mitchell

❮ Previous
Next ❯

Citations

Jan 6, 2011·Diabetes, Obesity & Metabolism·P AnagnostisD P Mikhailidis
Dec 15, 2010·BMC Endocrine Disorders·Deepson S ShyangdanNorman R Waugh
Sep 10, 2013·Cardiovascular Diabetology·John R Petrie
Aug 31, 2013·Diabetology & Metabolic Syndrome·Asfandyar Sheikh
Feb 11, 2012·Endocrine Reviews·John R Ussher, Daniel J Drucker
Jan 21, 2012·The Review of Diabetic Studies : RDS·Cendrine Cabou, Rémy Burcelin
Jun 16, 2012·Indian Journal of Endocrinology and Metabolism·Vishal Gupta
Aug 16, 2014·European Journal of Clinical Pharmacology·Xu-Ping YangYi-Lan Huang
Jul 6, 2014·Heart, Lung & Circulation·Dilshani JayawardeneRichard J MacIsaac
Mar 12, 2011·Expert Opinion on Investigational Drugs·Mikkel ChristensenJens J Holst
Dec 17, 2014·Expert Opinion on Drug Safety·Agostino Consoli, Gloria Formoso
Aug 14, 2012·British Journal of Clinical Pharmacology·Börje DarpöLisa Porter
Feb 11, 2012·British Journal of Clinical Pharmacology·Buddhike MendisPeter Mansell
Mar 11, 2015·Clinical Therapeutics·Cyrus V DesouzaAnery Patel
Apr 22, 2014·Molecular Metabolism·Alessandro Pocai
Jan 22, 2013·Diabetes Research and Clinical Practice·Susan Herzlinger, Edward S Horton
Jun 25, 2016·Nature Reviews. Endocrinology·Abd A TahraniClifford J Bailey
Mar 20, 2012·The American Journal of Cardiology·Steven G Chrysant, George S Chrysant
Jan 15, 2017·Cardiovascular Diabetology·Martin LorenzLawrence Blonde
Jan 20, 2017·Expert Opinion on Drug Safety·Niels B DalsgaardFilip K Knop

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.